A new solid target design for the production of 89 Zr and radiosynthesis of high molar activity [ 89 Zr]Zr-DBN.

Autor: Pandey MK; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA., Bansal A; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA., Ellinghuysen JR; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA., Vail DJ; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA., Berg HM; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA., DeGrado TR; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester MN 55906, USA.; Department of Radiology, University of Colorado Anschutz Medical Campus Aurora, CO 80045, USA.
Jazyk: angličtina
Zdroj: American journal of nuclear medicine and molecular imaging [Am J Nucl Med Mol Imaging] 2022 Feb 15; Vol. 12 (1), pp. 15-24. Date of Electronic Publication: 2022 Feb 15 (Print Publication: 2022).
Abstrakt: Due to the advent of various biologics like antibodies, proteins, cells, viruses, and extracellular vesicles as biomarkers for disease diagnosis, progression, and as therapeutics, there exists a need to have a simple and ready to use radiolabeling synthon to enable noninvasive imaging trafficking studies. Previously, we reported [ 89 Zr]zirconium- p -isothiocyanatobenzyl-desferrioxamine ([ 89 Zr]Zr-DBN) as a synthon for the radiolabeling of biologics to allow PET imaging of cell trafficking. In this study, we focused on improving the molar activity (A m ) of [ 89 Zr]Zr-DBN, by enhancing 89 Zr production on a low-energy cyclotron and developing a new reverse phase HPLC method to purify [ 89 Zr]Zr-DBN. To enhance 89 Zr production, a new solid target was designed, and production yield was optimized by varying, thickness of yttrium foil, beam current, irradiation duration and proton beam energy. After optimization, 4.78±0.33 GBq (129.3±8.9 mCi) of 89 Zr was produced at 40 µA for 180 min (3 h) proton irradiation decay corrected to the end of bombardment with a saturation yield of 4.56±0.31 MBq/µA. Additionally, after reverse phase HPLC purification the molar activity of [ 89 Zr]Zr-DBN was found to be in 165-316 GBq/µmol range. The high molar activity of [ 89 Zr]Zr-DBN also allowed radiolabeling of low concentration of proteins in relatively higher yield. The stability of [ 89 Zr]Zr-DBN was measured over time with and without the presence of ascorbic acid. The newly designed solid target assembly and HPLC method of [ 89 Zr]Zr-DBN purification can be adopted in the routine production of 89 Zr and [ 89 Zr]Zr-DBN, respectively.
Competing Interests: None.
(AJNMMI Copyright © 2022.)
Databáze: MEDLINE
Externí odkaz: